Literature DB >> 309485

In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens.

S A Rosenberg, S Schwarz, P J Spiess.   

Abstract

Growth factors (GM), produced by murine lymphoid cells incubated with Concanavalin A, have been used to grow cytotoxic lymphoid cells in culture. C57BL/6 and DBA/2 lymphoid cells were sensitized against each other in primary, secondary, and tertiary in vitro cultures. These sensitized cells were grown in vitro in GM and retained their cytotoxic properties. Cells grew in culture about 10-fold every 5 to 7 days for over 2 months. Initial growth of cytotoxic cells in GM resulted in marked enhancement of specific cytotoxicity that returned to original levels after subsequent subcultures. After five 10-fold cell culture generations some nonspecific cytotoxicity directed against the responding target cell strain appeared in continuous cultures. This technique for growing large numbers of cytotoxic cells may be of value in the development of adoptive immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309485

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Progress in the development of immunotherapy for the treatment of patients with cancer.

Authors:  S A Rosenberg
Journal:  J Intern Med       Date:  2001-12       Impact factor: 8.989

Review 2.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

3.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

Review 6.  Interleukin 2: biology and biochemistry.

Authors:  S Gillis
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

7.  Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.

Authors:  R H Wiltrout; E Gorelik; M J Brunda; H T Holden; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Immersion in the search for effective cancer immunotherapies.

Authors:  Steven A Rosenberg
Journal:  Mol Med       Date:  2021-06-16       Impact factor: 6.354

9.  The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes.

Authors:  S Gillis; N A Union; P E Baker; K A Smith
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

10.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.

Authors:  T J Eberlein; M Rosenstein; S A Rosenberg
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.